View Older Stories View More Recent Stories

Aug 18, 2020 07:00AM Akcea and Ionis to Present Phase 2 Results of AKCEA-APOCIII-L(Rx) in Late-Breaking Presentation at ESC Congress 2020
Aug 13, 2020 07:00AM Akcea Announces New Pricing and Reimbursement of WAYLIVRA® (volanesorsen) in Germany
Aug 5, 2020 07:00AM Ionis reports second quarter 2020 financial results and recent business achievements
Aug 4, 2020 04:05PM Akcea Reports Financial Results and Highlights for Second Quarter 2020
Jul 22, 2020 07:13AM Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 22, 2020 07:05AM Ionis Pharmaceuticals to hold second quarter 2020 financial results webcast
Jul 22, 2020 07:00AM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Austria for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
Jul 21, 2020 07:31AM Biogen (BIIB) Begins Phase 4 Study Evaluating Benefit of SPINRAZA (nusinersen) in Patients Treated with Zolgensma (onasemnogene abeparvovec)
Jul 21, 2020 07:30AM Biogen Plans to Initiate Phase 4 Study Evaluating Benefit of SPINRAZA® (nusinersen) in Patients Treated with Zolgensma® (onasemnogene abeparvovec)
Jul 21, 2020 07:00AM Akcea Therapeutics to Hold Second Quarter 2020 Financial Results Webcast
Jul 20, 2020 07:00AM Akcea Appoints New Senior Vice President, Global Medical Affairs
Jul 9, 2020 07:05AM Akcea Therapeutics (AKCA) Announces Appointment of New Chief Medical Officer
Jul 9, 2020 07:00AM Akcea Announces Appointment of New Chief Medical Officer
Jul 7, 2020 07:05AM Ionis Pharmaceuticals to hold neurology franchise webcast
Jun 29, 2020 07:00AM Akcea Appoints Tracy Palmer Berns as Chief Compliance Officer
Jun 17, 2020 07:00AM Akcea Therapeutics to Present at the BMO 2020 Prescriptions for Success Healthcare Conference
Jun 10, 2020 07:32AM Biogen (BIIB) Announces New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA Continue to Demonstrate Sustained Benefit From Treatment
Jun 10, 2020 07:30AM New Results From Landmark NURTURE Study Show That Pre-Symptomatic SMA Patients Treated With SPINRAZA® (nusinersen) Continue to Demonstrate Sustained Benefit From Treatment
Jun 9, 2020 07:00AM Akcea Appoints New Senior Vice President, Business Development and Corporate Strategy
Jun 8, 2020 07:02AM Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 8, 2020 07:00AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Italy for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 5, 2020 07:05AM Ionis Pharmaceuticals to present at upcoming virtual investor conferences
Jun 1, 2020 07:10AM Akcea (AKCA) announces approval for reimbursement of TEGSEDI in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
Jun 1, 2020 07:00AM Akcea announces approval for reimbursement of TEGSEDI® (inotersen) in Portugal for treatment of hereditary transthyretin amyloidosis with polyneuropathy
May 28, 2020 04:05PM Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
May 28, 2020 07:11AM Akcea (AKCA), Ionis (IONS) Announce Publication of L-T Clinical Data of TEGSEDI in Patients with Polyneuropathy Driven by hATTR Amyloidosis Demonstrating Sustained Improvements
May 28, 2020 07:00AM Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
May 28, 2020 07:00AM Akcea and Ionis Announce Publication of Long-Term Clinical Data of TEGSEDI® in Patients with Polyneuropathy Driven by Hereditary Transthyretin Amyloidosis Demonstrating Sustained Improvements and Eve
May 18, 2020 07:31AM Biogen (BIIB) Announces New SPINRAZA Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of SMA Patients
May 18, 2020 07:30AM New SPINRAZA® (nusinersen) Data Reinforce Sustained Efficacy and Longer-Term Safety Across Broad Range of Spinal Muscular Atrophy (SMA) Patients
May 18, 2020 07:01AM Akcea Therapeutics (AKCA) Announces Appointment of New CFO
May 18, 2020 07:00AM Akcea Announces Appointment of New Chief Financial Officer
May 14, 2020 04:07PM Akcea Therapeutics (AKCA) Announces Approval for Reimbursement of TEGSEDI in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 14, 2020 04:05PM Akcea Announces Approval for Reimbursement of TEGSEDI® (inotersen) in Spain for Treatment of Hereditary Transthyretin Amyloidosis with Polyneuropathy
May 7, 2020 07:00AM Akcea Expands Leadership Team with Appointment of Carla Poulson as Senior Vice President and Chief Human Resources Officer
May 6, 2020 07:00AM Ionis reports first quarter 2020 financial results and recent business achievements
May 5, 2020 04:05PM Akcea Reports Financial Results and Highlights for First Quarter 2020
May 1, 2020 07:05AM Ionis Pharmaceuticals to host 2020 virtual annual meeting of stockholders
Apr 22, 2020 07:05AM Ionis Pharmaceuticals to hold first quarter 2020 financial results webcast
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Apr 21, 2020 07:00AM Akcea Therapeutics to Hold First Quarter 2020 Financial Results Webcast
Apr 20, 2020 07:08AM Ionis Pharmaceuticals (IONS), Roche Report Complete Patient Enrollment of Global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 20, 2020 07:05AM Ionis and partner announce enrollment completion of global Phase 3 GENERATION HD1 study for Huntington's disease
Apr 8, 2020 07:05AM Ionis establishes $25,000 scholarship to help ALS patients in greater San Diego area participate in physical and mental wellness programs
Apr 7, 2020 07:05AM Ionis Pharmaceuticals to present at upcoming investor conferences
Apr 2, 2020 07:35AM Biogen (BIIB) Reports First Patient Treated with Higher Dose of SPINRAZA (nusinersen) in Phase 2/3 DEVOTE Study
Apr 2, 2020 07:30AM Biogen Announces First Patient Treated With Higher Dose of SPINRAZA® (nusinersen) in Phase 2/3 DEVOTE Study
Mar 24, 2020 07:04AM Akcea Therapeutics (AKCA) Announces Dr. Damien McDevitt as CEO
Mar 24, 2020 07:03AM Akcea Therapeutics (AKCA) Announces Appointment of Dr. Damien McDevitt as CEO
Mar 24, 2020 07:00AM Akcea Therapeutics Announces Appointment of Dr. Damien McDevitt as CEO
View More Recent Stories View Older Stories